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End-stage renal disease (ESRD) may be defined
as a state of renal insufficiency of such severity that
the affected individual is unable to carry out his usual
activities because of symptoms usually attributed to
the uremic syndrome. This state has been reached, or
is imminent, when the serum creatinine concentration
rises above 10 mg/ 100 ml and/or the creatinine clearance falls below 5 to 10 ml/min and reversible causes
of renal failure such as obstructive uropathy, bilateral
renal vascular disease, severe accelerated hypertension, hypercalcemic nephropathy, uric acid nephropathy, and certain immunologic diseases such as
Wegener granulomatosis have been excluded. Prospective analysis of a population of patients meeting
these biochemical criteria has clearly shown that at
least 80% will require dialysis within 150 days and
40% will require this method of treatment within 60
days to sustain life. 1 Thus, when ESRD is reached,
weighty decisions concerning the patient's care must
be made. It is the purpose of this paper to review the
management of ESRD and to point out some of the
problems which may complicate the several therapeutic modalities.
The alternative methods of management of the
patient with ESRD are dialysis and transplantation .
These two therapeutic modalities are by no means
mutually exclusive and, as we shall see, should be
considered complementary. However, virtually all
patients must undergo a period of dialysis, even those
awaiting transplantation. Therefore, dialysis is the
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first mode of treatment encountered by a patient
entering an ESRD program.
At the present time there are few absolute contraindications to entrance into an ESRD program for
dialysis and transplantation. However, patients with
uncontrolled psychotic behavior, extreme old age,
advanced artherosclerotic vascular disease, or disseminated malignancy a re probably not candidates
for therapy.
Principles of good conservative management of
renal failure such as restriction of dietary protein,
careful attention to fluid and electrolyte balance with
tailoring of dietary sodium intake to the obligatory
sodium loss, and the administration of sodium bicarbonate supplements and oral phosphate binders
where appropriate may postpone the absolute need
for dialysis or transplantation if introduced when the
patient has moderately severe renal insufficiency. Recent studies have demonstrated that the period of
conservative management can be prolonged even further by the administrati on of a special mixture of the
keto-analogues of the essential a mino acids.2 This
maneuver allows for the dietary administration of
very limited quantities of nitrogen and is predicated
on the assumption that some of the urea nitrogen will
be recycled into the synthesis of essential as well as
nonessential amino acids. Unfortunately, these ketoacids are not commercially available at present, but
perhaps will be in the future.
Survival rates for patients treated by hemodialysis at home and those who have received a wellmatched transplant from a living related donor are
both greater than 80% at two years.3 It is worth
noting, however, that this represents patient survival
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and not graft survival which is only about 70%, thus
indicating that some 10% to 15% of the transplant
recipients who survive two years have suffered an
undetermined amount of morbidity in association
with rejection of their graft. Survival with in-center
dialysis and cadaver transplantation is less good, with
a two-year survival rate of approximately 70% in each
case. 3 The two-year graft survival in patients with
cadaver transplants is less than 50%. These statistics
suggest the desirability of home dialysis and living
related donor transplantation, but do not demonstrate a clear superiority of in-center dialysis or cadaver transplantation. Thus, factors other than survival
must be considered in selecting a mode of therapy.
Age is a major factor which may influence therapeutic selection . Children and adolescents tend to
have diminished growth and maturation while on
dialysis 4 and they frequently rebel against the rigid
dialysis schedule. Therefore, most authorities favor
transplantation as a mode of therapy in the young. 5
On the other hand, older individuals with a wellestablished, stable lifestyle may prefer not to run the
risk of the lost time from work and the potential
complications of transplantation . The patient's psychological state also may be of importance in selecting a mode of therapy. Some older patients, like the
children, may find the confining life of the dialysis
patient to be more than they can tolerate and be
willing to risk the uncertainties of cadaver transplantation.
The presence of complicating medical disorders
may influence the type of management selected . Diabetics may fare better with transplantation because
progression of atherosclerotic vascular disease and
retinopathy may be less rapid than on dialysis. 5 Patients with certain enzyme defects such as Fabrey
disease may also benefit from transplantation because the transplanted organ may serve as a source of
the defective enzyme. 6 On the other hand, transplantation is contraindicated in patients with antibasement membrane antibody nephritis with circulating antibodies 7 and in patients with large quantities
of circulating cytotoxic antibodies 7 because of the
likelihood of rapid graft destruction after transplantation. Additionally, the immunosuppressive
medication given to patients may allow for enhanced
tumor growth, and most surgeons will not consider
performing transplantation in a patient with a history
of malignancy unless there is clear evidence that the
patient has been tumor-free for at least one year.7 The
presence of lower urinary tract dysfunction and an
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inadequate bladder are still considered relatively
strong contraindications to transplantation .
Having decided that a patient's life will be sustained, a decision must be made about the form of
dialysis to be instituted. Although chronic peritoneal
dialysis has been an effective modality in some
hands,8 most authorities consider it to be less desirable than chronic hemodialysis, and the remainder of
this discussion will be concerned with hemodialysis.
Two types of vascular access are available for
connecting the patient to a dialysis machine. These
are the silastic, external arteriovenous (AV) shunt 9
which protrudes through the skin and the internal
AV fistula communication, using the patient's own
vessels 10 or a foreign graft material. 11 The latter lies
immediately under the skin and must be punctured
with a needle at each dialysis. The fistula is preferred
by most physicians and patients because of the freedom of movement and the safety which it provides.
Where possible, it is our policy to anticipate the
ultimate need for dialysis and to have the surgeon
electively establish an AV fistula at about the time the
serum creatinine reaches a concentration of8 mg/100
ml. This allows time for maturation of the fistula
prior to its initial use, and obviates the need for
emergency surgery to establish vascular access in an
ill patient.
Hemodialysis is usually initiated in the medical
center, but when the patient has an acceptable helper,
every effort should be made to encourage the couple
to learn home dialysis. The training program can be
mastered by anyone of average intelligence and takes
about two months to complete. As mentioned previously, patients on home dialysis have better survival statistics and are better rehabilitated. 12
Whether dialysis is performed at home or in a
center facility, there are a number of common complications of which the physician should be aware.
Bacterial infection of the shunt or fistula is a frequent
problem that may lead to metastasization and requires aggressive drainage and antibiotic treatment. 13
Hepatitis B infection has been a frequent occurrence
among dialysis patients. 14 It presents a particular
problem in dialysis units because patients may become carriers and transmit the virus to staff and other
patients. Virtually all patients on dialysis have some
degree of anemia .15 In the past, transfusion of potential transplant candidates was kept to a minimum
because of possible sensitization to transplant antigens. However, recent evidence suggests that frequent
transfusions may actually enhance rather than inhibit

94
the frequency of organ acceptance. 16 Therefore,
transfusions, particularly of saline-washed red cells,
are now being given with less concern than in the
past. Pericarditis continues to be a frequent and
poorly understood complication in the dialysis patient and it does not always appear to be a manifestation of inadequate dialysis .17 Hypertension is seen
frequently in the dialysis population ahd may be related either to expansion of the extracellular fluid
volume or to the release of pressor substances from
the residual damaged kidneys .18 In the latter circumstance, bilateral nephrectomy may produce a dramatic return of the blood pressure to normal. 19 Neuropathy is frequently noted at the onset of dialysis
but seldom progresses if dialysis is adequate. 20 Impotence is seen more frequently than not in male dialysis
patients, and dialysis against a bath containing a high
concentration of zinc has recently been proposed as
effective therapy .21 As more patients are sustained
alive for prolonged periods of time it is becoming
clear that osteodystrophy22 and accelerated atherosclerosis21 are problems of great magnitude. Therapy
of the former includes the use of oral phosphate
binders to maintain the serum phosphorus concentration levels at normal , and a supplemental vitamin D
preparation to enhance intestinal calcium absorption;
there does not appear to be any effective therapy for
the latter.
Many of the problems mentioned above will be
corrected by a functioning transplant. However,
there are a number of problems which are unique to
the transplant population. Most of the difficulties
associated with early transplant rejection are managed by the transplant team prior to discharge from
the hospital after surgery, and these will not be considered here. Chronic rejection may occur late after
transplantation, is characterized by a slow deterioration in function , and is generally unresponsive to
therapy. Infection remains the major cause of morbidity and mortality among transplant patients. 23 Because of the constant need for immunosuppressive
medication these patients have an increased susceptibility to both common bacterial pathogens and to
opportunistic viruses such as herpes hominis and
cytomegalovirus; fungi such as cryptococcus and aspergillus; and protozoa such as pneumocystis and
toxoplasmosis . Hypertension also is a frequent complication of transplantation and may be difficult to
control. A diabetic diathesis may be brought out by
the administration of steroids as immunosuppressive
agents. 24 Osteoporosis may develop as a complication

FALLS: END-STAGE RENAL DISEASE

of long-term steroid administration. 24 The constant
immunosuppression may also allow for the development of tumor growth and there is a much higher
incidence of malignancy in transplant patients than in
a comparable, non-immunosuppressed population. 24
Gastrointestinal bleeding is a feared complication of
transplantation that is frequently fatal. 24 Consequently, many transplant surgeons perform prophylactic gastric surgery in any potential candidate
who has the slightest history of ulcer disease.
It is our feeling that selection of a proper therapeutic modality in a patient with ESRD requires
careful consideration of the medical, psychological,
social, and economic aspects of the patieht's illness.
His needs may change through the course of illness
and, as a consequence, the ESRD prescription may
require alteration. Thus, a patient might initially be
managed with home dialysis, receive a living related
donor transplant after a sibling decided to become a
donor, and return to home dialysis after rejection
occurred.
The economic costs of ESRD treatment are staggering. 25 At present there are more than 37,000 individuals receiving some type of ESRD therapy in the
United States at an annual cost of $902 million. By
1982 it is projected that the cost for 55,900 patients
will be 2.3 billion . Most patients are eligible for financial coverage of the major portion of their dialysis or
transplantation cost either via private insurance carrier, Medicare, or the Veterans Administration. At
present the annual cost of in-center dialysis is approximately $23,400 while that of home dialysis is
$12,480. The initial cost of hospitalization for transplant surgery is about $17,000. These estimates do
not include the cost of hospitalization for various
complications of either the dialysis or transplant
state; and, as suggested earlier, these may be formidable.
In the future, dialysis equipment may be made
more compact and a satisfactory portable dialyzer
may q_e developed. The use of sorbent materials may
allow dialysis with small quantities of fluid, and high
potency antithymocyte globulin may improve the
early survival of cadaver grafts. Techniques also may
be developed for the stimulation of blocking antibodies in the recipient which will allow for improved
graft survival with lower doses of immunosuppressive
drugs. However, none of these innovations seem
likely to dramatically change the management of
ESRD in the near future.
The management of ESRD has been briefly re-
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viewed; both dialysis and transplantation are useful
modalities of therapy and are not mutually exclusive.
Management in a giv'en patient should be designed to
best meet his medical, psychological, social, and economic needs.
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